Skip to main content

Table 4 CSF and serum analyses of patients with COVID-19

From: Neurological symptoms in COVID-19: a cross-sectional monocentric study of hospitalized patients

CSF parameters
Patient # of total 53 patients (see Additional file 1
(age)
Cells/μl (< 5) Total Protein g/l (0.2–0.4) Lactate mmol/l (1.1–2.4) Glucose mg/dl (40–70) Blood-brain-barrier dysfunction Oligoclonal Bands (Isoelectric focussing) SARS-CoV-2 PCR
2 (62)a 12 0.61 2.1 2 yes negative negative
20 (53) 3 0.42 2.0 85 no negative not available
21 (75) 1 0.18 1.4 41 no negative negative
23 (76) 2 0.34 1.7 55 no negative negative
32 (69) 10 0.95 3.5 87 yes negative negative
33 (59) 12 0.3 4.3 83 yes negative negative
37 (56) 2 0.39 2.2 80 no negative negative
45 (77) 2 0.31 1.5 64 no negative negative
53 (55)a 1 0.19 2.8 105 no negative negative
Specific serum analysis
Patient # (age) D-dimers ng/ml (< 500) Ferritin ng/ml (15–150) Il-2-Rc U/ml (158–623) Il-6 pg/ml (< 7.0) TNF-alpha pg/ml (< 8.1) NSE ng/ml (< 17)  
2 (62)a 13,662 1497 6455 4203 74.1 26  
20 (53) 292 232 452 22 10 n.a.  
21 (75) 1209 234 n.a. n.a. n.a. n.a.  
23 (76) 613 415 < 158 21 6.8 n.a.  
32 (69) 23,237 2277 943 1407 25 29  
33 (59) 25,243 6644 4343 331 44 31  
37 (56) 95,052 3501 2245 1408 27 51  
45 (77) 1170 1790 1007 1369 < 8 n.a.  
53 (55)a 24,754 5264 n.a. 636 n.a. n.a.  
  1. CSF Cerebrospinal fluid, Il-2-Rc Interleukin-2 receptor, Il-6 Interleukin-6, TNF-alpha Tumor necrosis factor, NSE Neuron-specific enolase, n.a. Not available
  2. apatient died during the course of the disease